



EmphyCorp N115 Rx Nasal Spray Drug Pipeline 1/24/2023

7 Drug Patents (2 New for Hypoxemia & Dyspnea, Apoptosis of Myofibroblasts) (x = completed)

Disease	Drug	Phase 1	Phase 2	Phase 3	NDA	Note
Pulmonary Fibrosis (ILD Orphan Drug Designation)	N115 Non-Steroidal Nasal Spray	X	X	X	→	\$2 to \$5 Billion Market
COVID-19 Treatment & Preventative (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Increases Nasal NO to kill Viruses/shuts down IL-6
Long COVID Treatment (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Treats Long COVID Symptoms
Influenza A&B Treatment & Preventative (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	→		Increases Nasal NO to kill Viruses / shuts down IL-6
Unmet Needs - Allergic Rhinitis, COPD (Diabetic, Hypertensive, Pregnant, Child)	N115 Non-Steroidal Nasal Spray w/ no adverse effects	X	X			\$24 Billion Market (30 to 60 Million People in US Alone)
COPD – All Ages	N115 Non-Steroidal Nasal Spray	X	X			\$2 to \$4 Billion Market
Cystic Fibrosis (ILD Orphan Drug Designation)	N115 Non-Steroidal Nasal Spray	X	X			\$2 to \$3 Billion Market
Allergic Rhinitis (70% Lower Steroids Version)	N115 Nasal Spray	X	X			\$2 Billion Market
COPD (70% Lower Steroids Version)	N115 Nasal Spray or Oral Spray	X	X			\$2 Billion Market
Alzheimer's	N115 Nasal Spray	X	X			\$2 Billion Market
Concussions	N115 Nasal Spray	X	X			\$2 Billion Market
Cancer Pre-Treatment	N115 Nasal Spray	X	X			\$2 Billion Market
OTC Nasal Spray sold mostly in North America and in China	OTC N115 Nasal Spray	(1) US and (3) Chinese Approved Nasal Sprays				3 Million Patients Treated